Barrick Surges 1.53% with 272nd-Ranked $0.44 Billion Volume as Analysts Back Earnings and Upgrades
On August 13, 2025, BarrickB-- (B) surged 1.53% with a trading volume of $0.44 billion, a 33.49% increase from the prior day, ranking 272nd in market activity. Analysts highlighted renewed momentum amid strong earnings performance and positive estimate revisions. The stock’s 9.64% weekly gain outperformed the Zacks Mining - Gold industry’s 7.4% rise, while its 25.87% quarterly appreciation contrasted with the S&P 500’s 10.57% gain. Elevated trading volume and upward revisions to 2024 earnings estimates further supported its bullish trajectory.
Recent analyst activity underscored confidence in Barrick’s outlook. Canaccord Genuity reiterated a Buy rating with a $39 target, while RBC Capital and BMO Capital upgraded their recommendations. Institutional ownership remained robust, with Vanguard Group and Capital International Investors collectively holding over $2.2 billion in shares. Notably, hedge fund activity included new positions by major players, reflecting growing institutional interest.
Options market data revealed heightened call option activity, with 90,999 contracts traded—a 161% spike from typical volumes. This surge, combined with Barrick’s 16.4% year-over-year revenue growth and 17.46% net margin, signaled short-term speculative positioning. However, insider selling trends over the past quarter introduced caution, as corporate insiders reduced holdings amid mixed analyst ratings.
A backtest of the top 500 volume stocks held for one day from 2022 to 2025 yielded a 0.98% average daily return and 31.52% cumulative return over 365 days. This strategy captured market momentum but remained exposed to volatility, illustrating the risks of timing-driven approaches in a high-volume environment.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet